Andere Sprachen Cellectis S.A.

Aktien

A0MKPR

FR0010425595

ALCLS

Biotechnologie

Markt geschlossen - Euronext Paris Andere Börsenplätze 17:55:00 10.07.2026			Nachbörslich 21:58:00
2,590 ^EUR	-4,15 %		2,646	+2,16 %

08.07.	In den USA als American Depositary Receipts gehandelte europäische Aktien fallen im Handel am Mittwoch deutlich	MT
02.07.	In den USA als American Depositary Receipts gehandelte europaeische Aktien legen im Handel am Donnerstag deutlich zu	MT

Andere Sprachen

08.07.	European Equities Traded in the US as American Depositary Receipts Decline Sharply in Wednesday Trading
02.07.	European Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading
30.06.	European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
29.06.	European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading
25.06.	Résultats de l’Assemblée Générale Mixte de Cellectis du 25 juin 2026
25.06.	Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026
25.06.	European Equities Traded in US as ADRs Rise in Thursday Trading
24.06.	European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
22.06.	European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
19.06.	Agenda des dividendes et des AG de la semaine : session dividendes pour la galaxie Bolloré
18.06.	European Equities Traded in the US as American Depositary Receipts Little Changed in Thursday Trading
16.06.	European Equities Traded in the US as American Depositary Receipts Slightly Higher in Tuesday Trading
11.06.	Cellectis Says Phase 1 Lasme-cel Study Shows 100% Response Rate in B-Cell Leukemia Patients
11.06.	Cellectis S.A. Presents Final Phase 1 Results of Lasme-Cel and Preliminary Results on Eti-Cel At Eha 2026 Congress
11.06.	Cellectis dévoile les résultats finaux de phase 1 pour lasmé-cel et des données préliminaires pour éti-cel à l'EHA 2026
11.06.	Cellectis dévoile des résultats de phase 1
11.06.	Bourse : J-1 avant SpaceX, Oracle à la peine, contrat pour Airbus
11.06.	Cellectis présente les résultats finaux de phase 1 pour lasmé-cel et des résultats préliminaires pour éti-cel au congrès de l’EHA 2026
11.06.	Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress
11.06.	Une bonne grosse purge avant SpaceX
10.06.	European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading
10.06.	Bourse : Airbus veut rebondir sur le SCAF, Legrand se renforce, le marché attend Oracle
10.06.	Ça ne respire pas la sérénité à Wall Street
10.06.	Cellectis Obtains Regenerative Medicine Advanced Therapy Designation for Potential Leukemia Treatment
09.06.	Cellectis S.A. Receives FDA RMAT Designation for Lasme-Cel, the First Allogeneic Car-T Therapy in A Pivotal Trial for Patients with R/R B-All